Close Menu

Breaking News

Genomic, transcriptomic, proteomic, and post-transcriptional modification features in nearly 100 GBM tumors offered clues to tumor biology, revealing four immune subtypes.

The company said it plans to use the funds to build out its annotated immune cell atlas and to expand its functional genomics capabilities.

Investors reacted favorably to a report Wednesday evening saying the Carlsbad, California-based firm is working with a financial advisor on a potential sale.

The test was previously cleared by the FDA for use with ethylenediaminetetraacetic acid plasma samples to manage BK virus in transplant patients.

The New Jersey-based cancer drug-discovery services provider said it had signed agreements to sell the shares to unnamed institutional investors.

The firm also announced a COVID-19 testing deal with George Mason University and a CyTOF supply and distribution agreement with Zhejiang PuLuoTing Health Technology in China.

Q4 revenues totaled $27.1 million, down from $27.9 million in Q4 of 2019 but beating the average Wall Street estimate of $25.4 million.

In the first 53,831 samples, the researchers detected more than 410 million variants. almost 80 percent of which had not been described before.

Life Genomics markets a noninvasive prenatal test for chromosomal abnormalities, a genetic disease carrier test, and an Alzheimer's disease risk test.

The deal, which values Sema4 at approximately $2 billion and will deliver up to $793 million in gross proceeds, is expected to close during the second quarter.

The company plans to use the new funding, which will come from the sale of convertible senior notes due 2028, to support unspecified future growth initiatives.

The firm will use the proceeds to expand its tissue and liquid biopsy product portfolio, as well as to fund future pharma and biotechnology partnerships.

Qiagen reported total revenues of $571.2 million in Q4 compared to $413.5 million a year ago, beating analysts' expectation of $548.9 million.

A new study lends credence to the idea that pre-existing anti-cancer immunity depends heavily on patients' genetic background, according to one of the researchers.

The researchers also found SARS-CoV-2 neutralizing antibodies in Thai bats and pangolins, suggesting that the progenitor virus may have originated outside of China.

A single healthcare-focused investor will purchase 2.78 million shares of common stock, 5.55 million prefunded warrants, and an additional 4.17 million shares of common stock.

The firm's molecular diagnostics revenues rose 49 percent year over year to $57.8 million from $38.8 million in Q4 2019.

Initial paleoanthropological analyses had suggested an earlier arrival of modern humans in the region, contradicting molecular findings.

Spatial expression features in six layers of the human dorsolateral prefrontal cortex provided a look at laminar markers and discovered ties to neuropsychiatric disease genes.

Both germline variants and somatic tumor variants linked to disease are more likely to disrupt protein-protein interactions than other variants.

The test, which was developed by researchers at the Cleveland Clinic and the University of Alabama, looks for RNA molecules in urine that indicate rejection.

The Chinese firms have agreed to work together to develop commercial analytical and artificial intelligence-based computing platforms for single-cell genomics.

Oxford Immunotec's T-SPOT Discovery SARS-CoV-2 kit adds a research test for measuring the T cell response to SARS-CoV-2 infection to GCMS' portfolio.

Last week, GenomeWeb's readers were most interested in the efforts of New York City and the US Congress to boost NGS-based surveillance of SARS-CoV-2.

The firm and cancer centers will use radiomics, clinical, biologic, and genomics data to predict responses to neoadjuvant nivolumab plus chemo in NSCLC.  

Pages

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.